- Home
- AMST vs IMNN Comparison
AMST vs IMNN Comparison
Compare AMST & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMST
- IMNN
- Stock Information
- Founded
- AMST 2017
- IMNN 1982
- Country
- AMST United States
- IMNN United States
- Employees
- AMST N/A
- IMNN N/A
- Industry
- AMST Computer Software: Prepackaged Software
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- AMST Technology
- IMNN Health Care
- Exchange
- AMST Nasdaq
- IMNN Nasdaq
- Market Cap
- AMST 13.3M
- IMNN 12.1M
- IPO Year
- AMST 2020
- IMNN 1985
- Fundamental
- Price
- AMST $2.88
- IMNN $6.40
- Analyst Decision
- AMST
- IMNN Buy
- Analyst Count
- AMST 0
- IMNN 2
- Target Price
- AMST N/A
- IMNN $210.00
- AVG Volume (30 Days)
- AMST 40.5K
- IMNN 288.2K
- Earning Date
- AMST 09-29-2025
- IMNN 08-05-2025
- Dividend Yield
- AMST N/A
- IMNN N/A
- EPS Growth
- AMST N/A
- IMNN N/A
- EPS
- AMST N/A
- IMNN N/A
- Revenue
- AMST $82,544.00
- IMNN N/A
- Revenue This Year
- AMST N/A
- IMNN N/A
- Revenue Next Year
- AMST N/A
- IMNN N/A
- P/E Ratio
- AMST N/A
- IMNN N/A
- Revenue Growth
- AMST N/A
- IMNN N/A
- 52 Week Low
- AMST $2.00
- IMNN $4.83
- 52 Week High
- AMST $6.27
- IMNN $41.22
- Technical
- Relative Strength Index (RSI)
- AMST 46.22
- IMNN 38.73
- Support Level
- AMST $2.74
- IMNN $6.65
- Resistance Level
- AMST $2.94
- IMNN $7.21
- Average True Range (ATR)
- AMST 0.17
- IMNN 0.70
- MACD
- AMST -0.02
- IMNN 0.17
- Stochastic Oscillator
- AMST 35.51
- IMNN 5.94
About AMST Amesite Inc.
Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).